Compare Novartis AG (NVS) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Paycom Software Inc — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while Paycom Software Inc trades at $232.22 (market cap $10.36B). The key difference: Novartis AG is far larger — about 25.9× Paycom Software Inc's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Paycom Software Inc for 84 Days on average.
| NVS | PAYC | |
|---|---|---|
Market Cap | $268.57B | $10.36B |
Volume | 1,532,573 | 666,294 |
Sector | Health | Technology |
52-Week High | $168.62 | $240.52 |
52-Week Low | $121.80 | $113.59 |
Typical Hold Time | 82 Days | 84 Days |
Enterprise Value | $309.89B | $11.15B |
Dividend Yield | 3.31% | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
Paycom Software (PAYC) trades at $232.22, up 3.86% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $2.78 versus $2.38 expected, driven by 10% revenue growth and margin expansion. The company raised full-year 2026 guidance, targeting 7-8% revenue growth and improved EBITDA margins. Cash flow remains robust, with 2025 operating cash flow at $678.9 million.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and market volatility. Analyst consensus is mixed with a $207.75 price target below the current price, suggesting cautious optimism. Institutional buying activity supports bullish sentiment, though valuation multiples like a P/E of 24.33 warrant monitoring for sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
